Equillium

CompanyUnited States

Equillium develops one asset, in phase 1 (EQ504 in inflammatory diseases). Mostly peptide acting on inflammation; based in the United States.

1
Asset
Furthest stage
Phase 1
0
Trials
0
Signals

Pipeline

1
  • EQ504

    Multi-cytokine inhibitor targeting immunomodulatory pathways

    Phase 1, Peptide, Inflammation, inflammatory diseases

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Similar companies6

Intelligence